Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only
      transparent image 3

      ▼This medicine (AQUIPTA®) is subject to additional monitoring. This will allow quick identification of new safety information.

      AQUIPTA® is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.1,2 AQUIPTA® is not recommended during pregnancy. A decision must be made whether to discontinue breastfeeding or to discontinue AQUIPTA® therapy taking into account the benefit of breastfeeding for the child and benefit of therapy for the woman.1,2

      Please consult the full Summary of Product Characteristics.

      CGRP, calcitonin gene-related protein

      Reference:

      1. AQUIPTA® UK Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/15049/smpc. Accessed November 2023

      2. AQUIPTA® (atogepant) EU Summary of Product Characteristics. August 2023. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/aquipta. Accessed November 2023

      Reference:

      1. AQUIPTA® UK Summary of Product Characteristics. Available at: https://www.medicines.org.uk. Accessed November 2023

      2. AQUIPTA® (atogepant) EU Summary of Product Characteristics. August 2023. Available at: https://www.ema.europa.eu. Accessed November 2023

      AQUIPTA® PRESCRIBING INFORMATION

      UK-NEUR-230022 | Date of preparation: November 2023.

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected]

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.